Ebola puts focus on drugs made in tobacco plants

Aug 15, 2014 by Malcolm Ritter
A tobacco flower waves in a dew-covered field outside Rolesville, N.C., on Wednesday, Aug. 13, 2014. Researchers are using a relative of this smoking leaf to grow medicines for the flu and even, perhaps, ebola. (AP Photo/Allen G. Breed)

It's an eye-catching angle in the story of an experimental treatment for Ebola: The drug comes from tobacco plants that were turned into living pharmaceutical factories.

Using plants this way—sometimes called "pharming"—can produce complex and valuable proteins for medicines. That approach, studied for about 20 years, hasn't caught on widely in the pharmaceutical industry.

But some companies and academic labs are pursuing it to create medicines and vaccines against such targets as HIV, cancer, the deadly Marburg virus and norovirus, known for causing outbreaks of stomach bug on cruise ships, as well as Ebola.

While most of the work in this area uses a , it's just a relative of the plant used to make cigarettes.

"It's definitely not something you smoke," said Jean-Luc Martre, a spokesman for Medicago, a Canadian company that's testing flu vaccines made with tobacco plants.

Medicago has a new production facility in Research Triangle Park, North Carolina. Once approved by federal authorities, it's expected to be able to make 30 million doses of seasonal a year, or 120 million vaccine doses to fight a major outbreak of "pandemic" flu if the government requests it.

Scientists favor tobacco plants because they grow quickly and their biology is well understood, said Ben Locwin, a pharmaceutical biotech consultant in Portsmouth, New Hampshire, who is considered an expert on plant-produced medicines by the American Association of Pharmaceutical Scientists.

The North Carolina operation can handle as many as 90,000 plants. Under the whir of fans, rows of young seedlings grow for about a month, until they are about a foot tall. Then they are taken by robots to another section of the facility, turned upside down and dipped in a tank to be "infiltrated" with whatever proteins they wish to grow.

Early-morning dew glistens on a tobacco leaf in a field outside Rolesville, N.C., on Wednesday, Aug. 13, 2014. Researchers are using a relative of this smoking leaf to grow medicines for the flu and even, perhaps, Ebola. (AP Photo/Allen G. Breed)

There are a number of Ebola treatments and vaccine in development, and one comes from tobacco plants grown in specialized greenhouses at another operation, Kentucky BioProcessing, in Owensboro, Kentucky.

That , called ZMapp, uses proteins called antibodies, and is designed to inactivate the Ebola virus and help the body kill infected cells. It hasn't been tested in people but had shown promise in animal tests, so it was tried in three people sickened by Ebola in West Africa—two U.S. aid workers and a Spanish missionary priest, who later died.

The last few doses available are in Liberia. Kentucky BioProcessing, which produces it for the San Diego-based Mapp Biopharmaceutical, said it would take several months to make more, but it is working to increase production.

In this undated file photo provided by Kentucky BioProcessing, tobacco plants are grown in a controlled environment at the Kentucky BioProcessing facility in Owensboro, Ky. The company is using tobacco plants grown at this facility to help manufacture an experimental drug to treat patients infected with Ebola. In the case of the Americans being treated for Ebola, the treatment uses proteins called antibodies to inactivate the Ebola virus and help the body kill infected cells. (AP Photo/Kentucky BioProcessing, File)

In general, the idea behind pharming is to slip the genetic blueprints for a particular protein into a plant and let the plant's protein-making machinery go to work. Then the protein can be extracted from plant tissues. While tobacco plants are a mainstay of such work, proteins also have been produced in other plants, such as safflower and potato.

In fact, the only medicine made this way that the federal government has approved for general use in people is made in a laboratory from cells of carrot plants. It treats a genetic illness called Gaucher's disease. The drug was approved in 2012 by the Food and Drug Administration.

A plant-made vaccine for a chicken disease gained approval from the Department of Agriculture in 2006 but was never brought to market. Another plant-produced product to fight germs that cause tooth decay has been approved for use in Europe.

The lack of any stronger track record for approved drugs in the United States is a key reason why the plant-based technology hasn't been embraced more fully, Locwin said. That's despite the fact that it offers benefits like lower cost than the standard approach of using vats of cells from mammals to churn out complex proteins, Locwin said.

A ladybug prepares to lift off from a bedewed tobacco plant near Rolesville, N.C., on Wednesday, Aug. 13, 2014. Researchers are using a relative of this smoking leaf to grow medicines for the flu and even, perhaps, ebola. (AP Photo/Allen G. Breed)

Some companies use cells from bacteria instead, but they can't always produce the complicated proteins that drug companies need, he said. The plant-based approach "has a tremendous amount of promise, but it doesn't yet have the FDA blessing across the board to be able to say this is successful" and a proven way to get a drug to market, he said.

And it would cost companies money to change over to the new technology, he said.

Plant-based drugs have attracted the attention and funding of the federal government, however, as a fast and cheap approach to make a lot of vaccine material in case of terrorist attacks, said Daniel Tuse (pronounced too-SAY'), a consultant and managing director of Intrusept Biomedicine, which also works with tobacco plants in Owensboro.

Early-morning dew glistens on a tobacco leaf in a field outside Rolesville, N.C., on Wednesday, Aug. 13, 2014. Researchers are using a relative of this smoking leaf to grow medicines for the flu and even, perhaps, Ebola. (AP Photo/Allen G. Breed)

If a new germ appears, genetic material from it can be quickly inserted into plants, and large numbers of the plants can churn out supplies of material for vaccines or treatments, he said.

The plant-based experimental Ebola treatment was developed with government support.

Explore further: Biodesign researcher helped develop tobacco-based platform for Ebola vaccine development

5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

FDA lifts hold on experimental Ebola drug

Aug 07, 2014

Federal health authorities have eased safety restrictions on an experimental drug to treat Ebola, a move that could clear the way for its use against an unprecedented outbreak of the deadly virus in West Africa.

Scientists racing to test Ebola vaccines in humans

Aug 14, 2014

Scientists are racing to begin the first human safety tests of two experimental Ebola vaccines, but it won't be easy to prove that the shots and other potential treatments in the pipeline really work.

Spanish Ebola patient gets experimental drug

Aug 11, 2014

Spain has imported a U.S.-made experimental Ebola drug to treat a Spanish missionary priest evacuated from Liberia last week after testing positive for the killer virus.

Recommended for you

Battling superbugs with gene-editing system

13 hours ago

In recent years, new strains of bacteria have emerged that resist even the most powerful antibiotics. Each year, these superbugs, including drug-resistant forms of tuberculosis and staphylococcus, infect ...

For legume plants, a new route from shoot to root

Sep 19, 2014

A new study shows that legume plants regulate their symbiotic relationship with soil bacteria by using cytokinins—signaling molecules— that are transmitted through the plant structure from leaves into ...

Controlling the transition between generations

Sep 18, 2014

Rafal Ciosk and his group at the FMI have identified an important regulator of the transition from germ cell to embryonic cell. LIN-41 prevents the premature onset of embryonic transcription in oocytes poised ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Doug_Huffman
not rated yet Aug 15, 2014
... slip the genetic blueprints for a particular protein into a plant and let the plant's protein-making machinery go to work.
Definitely genetic manipulation engineered organism. Poor Luddites, they can't have any, it's GMO.